Chong Kun Dang Holdings Corp. (KRX:001630)
42,600
-400 (-0.93%)
Jun 4, 2026, 11:35 AM KST
Chong Kun Dang Holdings Revenue
Chong Kun Dang Holdings had revenue of 240.27B KRW in the quarter ending March 31, 2026, a decrease of -2.58%. This brings the company's revenue in the last twelve months to 952.66B, down -0.18% year-over-year. In the year 2025, Chong Kun Dang Holdings had annual revenue of 959.01B with 0.13% growth.
Revenue (ttm)
952.66B
Revenue Growth
-0.18%
P/S Ratio
0.21
Revenue / Employee
25.75B
Employees
37
Market Cap
204.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 959.01B | 1.26B | 0.13% |
| Dec 31, 2024 | 957.75B | 77.97B | 8.86% |
| Dec 31, 2023 | 879.78B | -29.18B | -3.21% |
| Dec 31, 2022 | 908.96B | -17.01B | -1.84% |
| Dec 31, 2021 | 925.98B | 67.86B | 7.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suheung | 743.02B |
| Daewon Pharmaceutical | 605.66B |
| Samjin Pharmaceuticals | 274.03B |
| Whan In Pharm | 266.19B |
| JW Lifescience | 252.72B |
| Boditech Med | 165.84B |
| Yungjin Pharm. | 158.79B |
| REYON Pharmaceutical | 145.22B |